Lantheus
🇺🇸 NASDAQ:LNTH
•
Dec 31, 2024
Lantheus Q4 2024 Earnings Report
Lantheus reported solid revenue growth driven by radiopharmaceutical sales despite a GAAP net loss for Q4 2024.
Key Takeaways
Lantheus reported worldwide revenue of $391.1 million for Q4 2024, a 10.5% increase compared to the same period in 2023. PYLARIFY achieved record net sales, but the company posted a GAAP net loss of $11.8 million for the quarter. Adjusted earnings per share were $1.59, reflecting continued growth in radiopharmaceuticals.
Worldwide revenue of $391.1 million, up 10.5% year-over-year.
GAAP net loss of $11.8 million for the quarter.
Sales of PYLARIFY reached $266.0 million, up 15.7%.
Free cash flow increased 41.1% to $141.4 million.
Lantheus Revenue
Lantheus EPS
Lantheus Revenue by Segment
Forward Guidance
For 2025, Lantheus expects revenue between $1.545 billion and $1.610 billion, with adjusted fully diluted EPS in the range of $7.00 to $7.20.
Positive Outlook
- Revenue projected to reach up to $1.610 billion.
- Adjusted EPS expected to be as high as $7.20.
- Continued focus on expanding the radiopharmaceutical portfolio.
- Strong pipeline with multiple strategic acquisitions planned.
- Enhanced cash flow position with over $900 million in cash.
Challenges Ahead
- Ongoing GAAP losses impacting bottom line.
- Decreased revenue from strategic partnerships.
- Higher operating expenses reported for the quarter.
- Market volatility impacting investment performance.
- Potential challenges in securing regulatory clearances for acquisitions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income